2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow INX-08189: new trials by email Literature Review of INX-08189 trials Research Report on INX-08189
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a - Hepatitis C | Phase 2 | Terminated | Bristol-Myers Squibb | 210 | 2012-05-01 | 2015-11-04 |
| Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects INX-08189, Placebo matching with INX-08189, Ribavirin - HCV (Genotype 1) | Phase 1 | Completed | Bristol-Myers Squibb | 70 | 2010-10-01 | 2012-07-12 |
| A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects INX-08189, Placebo - Healthy | Phase 1 | Completed | Bristol-Myers Squibb | 42 | 2010-05-01 | 2012-06-22 |
Hepatitis C (2) · Hepatitis, Chronic (1)
United States (2) · Puerto Rico (1)